Tenascin‐C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression

Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype

(2020) Claire Deligne et al.   Cancer Immunology Research

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

(2020) Rachael M. Zemek et al.   Frontiers in Immunology

Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation

(2020) Zhi-Ling Li et al.   Nature Communications

Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma

(2020) Caroline Spenlé et al.   Cancer Immunology Research

Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker

(2020) Kenneth Emancipator   AAPS Journal

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Tenascin-C increases lung metastasis by impacting blood vessel invasions

(2019) Zhen Sun et al.   MATRIX BIOLOGY

Targeted matrisome analysis identifies thrombospondin-2 and tenascin-C in aligned collagen stroma from invasive breast carcinoma

(2018) Lucas A. Tomko et al.   Scientific Reports

Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis

(2018) Fan Yang et al.   CANCER RESEARCH

Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma

(2017) Zhaoting Yang et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

The CXCL12/CXCR7 signaling axis, isoforms, circadian rhythms, and tumor cellular composition dictate gradients in tissue

(2017) Phillip C. Spinosa et al.   PLoS One

Tenascin-C at a glance

(2016) Kim S. Midwood et al.   JOURNAL OF CELL SCIENCE

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

(2016) S Lefort et al.   ONCOGENE

Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation

(2015) E. Jachetti et al.   CANCER RESEARCH

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Spatial organization of the tenascin-C microenvironment in experimental and human cancer

(2015) Caroline Spenlé et al.   Cell Adhesion & Migration

CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy

(2015) Urszula M. Domanska et al.   NEOPLASIA

The extracellular matrix modulates the hallmarks of cancer

(2014) M. W. Pickup et al.   EMBO REPORTS

Identification and Characterization of Circulating Variants of CXCL12 from Human Plasma: Effects on Chemotaxis and Mobilization of Hematopoietic Stem and Progenitor Cells

(2014) Rudolf Richter et al.   STEM CELLS AND DEVELOPMENT

CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems

(2014) Alice Guyon   Frontiers in Cellular Neuroscience

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain

(2013) Laura De Laporte et al.   PLoS One

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tenascin-C Downregulates Wnt Inhibitor Dickkopf-1, Promoting Tumorigenesis in a Neuroendocrine Tumor Model

(2013) Falk Saupe et al.   Cell Reports

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

(2012) G. Erdag et al.   CANCER RESEARCH

The extracellular matrix: A dynamic niche in cancer progression

(2012) Pengfei Lu et al.   JOURNAL OF CELL BIOLOGY

Cancer classification using the Immunoscore: a worldwide task force

(2012) Jérôme Galon et al.   Journal of Translational Medicine

Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2

(2011) Chuang Chen et al.   BIOMATERIALS

Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs

(2011) Thordur Oskarsson et al.   NATURE MEDICINE

miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors

(2011) Espen Enerly et al.   PLoS One

The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis

(2010) Chuang Chen et al.   BIOMATERIALS

Oxidative stress promotes myofibroblast differentiation and tumour spreading

(2010) Aurore Toullec et al.   EMBO Molecular Medicine

Extracellular Matrix of Glioblastoma Inhibits Polarization and Transmigration of T Cells: The Role of Tenascin-C in Immune Suppression

(2010) J.-Y. Huang et al.   JOURNAL OF IMMUNOLOGY

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

Collagen VI Is a Subepithelial Adhesive Target for Human Respiratory Tract Pathogens

(2009) Marta Bober et al.   Journal of Innate Immunity

Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease

(2009) Kim Midwood et al.   NATURE MEDICINE